Demonstrates medium- to long-term strategies prioritizing drug approval and\u4e0a\u5e02 in the oncology field. The scheduled completion date for Phase III trials is September of this year, with results expected within this period. The company is negotiating license and sales partnerships with multiple firms, promoting multiple development pipelines including anti-aging and CML. Formulation development is primarily considered for oral drugs in-house, while collaborations are anticipated in other areas such as dermatology, ophthalmology, and oral medicine. The delay in Aillion’s Phase II trial for hair loss is attributable to challenges faced by the company, and responses regarding the XPRIZE are currently withheld. The development of veterinary pharmaceuticals aims to align with human medicine and proceed to commercialization at appropriate timing.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4889","jir_company_name":"Lenascience Inc.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-06-29","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/06\/4889-20260629-01.pdf","jir_short_summary":"Demonstrates medium- to long-term strategies prioritizing drug approval and\u4e0a\u5e02 in the oncology field. The scheduled completion date for Phase III trials is September of this year, with results expected within this period. The company is negotiating license and sales partnerships with multiple firms, promoting multiple development pipelines including anti-aging and CML. Formulation development is primarily considered for oral drugs in-house, while collaborations are anticipated in other areas such as dermatology, ophthalmology, and oral medicine. The delay in Aillion's Phase II trial for hair loss is attributable to challenges faced by the company, and responses regarding the XPRIZE are currently withheld. The development of veterinary pharmaceuticals aims to align with human medicine and proceed to commercialization at appropriate timing.","jir_summary":"### Business Strategy and Clinical Development\nLenascience positions drug approval and\u4e0a\u5e02 in the oncology field as its primary goal, concurrently advancing multiple development pipelines as sources of medium- to long-term growth. The results of Phase III trials are expected to be announced within this fiscal year. Discussions are underway with multiple companies regarding potential expanded indications and licensing and sales collaborations upon approval. The company aims to flexibly develop strategies across multiple fields, including anti-aging, to maximize corporate value.\n\n### Product Development and Collaboration Strategy\nWhile considering in-house development of oral formulation as a key option, the company recognizes the need for collaborations in fields such as dermatology, ophthalmology, and dentistry. The delay in Aillion's Phase II trial for hair loss is due to issues within the company, and ongoing proposals are aimed at early implementation. The timing of disclosure of XPRIZE results remains unconfirmed at this stage. The company prioritizes the development of pharmaceuticals for humans, while veterinary medicine will be advanced to commercialization at appropriate timing, considering both market potential and alignment with human pharmaceuticals.","jir_financial_highlights":"Scheduled completion of Phase III trial: Scheduled for September of this year (Unknown)\nInclusion of Aillion's revenue in this period's earnings forecast: Not included (Unknown)","jir_category":"","jir_hashtags":"#Lenascience, #IRgeneral, #JapanStocks","jir_key_figures":"Scheduled completion of Phase III trial: September of this year\nInclusion of Aillion\u2019s revenue in this period's earnings forecast: Unknown\nIn-house formulation development consideration: Unknown","jir_meta_title":"\u3010Lenascience\u3011Q&A format corporate disclosure\uff5cJune 29, 2026","jir_meta_description":"Summary of Lenascience's shareholder Q&A disclosures. Prioritizes drug approval and\u4e0a\u5e02 in the oncology field, timing of Phase III trial results, partnership strategies, formulation development policies, reasons for Aillion\u2019s delays, and XPRIZE explanations.","jir_og_title":"\u3010Lenascience\u3011Q&A Disclosure: Oncology Strategy and Partnership Policies","jir_og_description":"Lenascience prioritizes drug approval and\u4e0a\u5e02, promotes multiple development pipelines. Phase III trial results expected within this fiscal year, with explanations of partnership considerations and in-house formulation development policies.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":57877,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"general_ir","footnotes":""},"sector":[],"importance":[],"class_list":["post-72391","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n